HC Wainwright Reaffirms “Buy” Rating for Jade Biosciences (NASDAQ:JBIO)

Jade Biosciences (NASDAQ:JBIO)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $55.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 291.46% from the company’s current price.

JBIO has been the subject of several other reports. Wedbush restated an “outperform” rating on shares of Jade Biosciences in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Jade Biosciences in a report on Friday, September 11th. Jefferies Financial Group restated a “buy” rating and set a $48.00 price target on shares of Jade Biosciences in a report on Tuesday, August 11th. Wall Street Zen cut shares of Jade Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, September 12th. Finally, BTIG Research raised their price target on shares of Jade Biosciences from $74.00 to $77.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $51.75.

Jade Biosciences Price Performance

Shares of JBIO opened at $14.05 on Thursday. The firm’s 50 day moving average is $19.69 and its 200-day moving average is $19.74. The stock has a market capitalization of $893.58 million, a P/E ratio of -7.32 and a beta of 1.45. Jade Biosciences has a 12-month low of $8.16 and a 12-month high of $28.00.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities research analysts forecast that Jade Biosciences will post -2.89 EPS for the current fiscal year.

Institutional Trading of Jade Biosciences

Institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC acquired a new stake in Jade Biosciences in the first quarter valued at approximately $43,557,000. Baker BROS. Advisors LP acquired a new stake in Jade Biosciences in the fourth quarter valued at approximately $25,323,000. Avidity Partners Management LP lifted its stake in Jade Biosciences by 24.3% in the fourth quarter. Avidity Partners Management LP now owns 1,400,708 shares of the company’s stock valued at $21,613,000 after acquiring an additional 273,522 shares during the last quarter. Stempoint Capital LP acquired a new stake in Jade Biosciences in the first quarter valued at approximately $2,164,000. Finally, Renaissance Technologies LLC lifted its stake in Jade Biosciences by 94.0% in the first quarter. Renaissance Technologies LLC now owns 135,039 shares of the company’s stock valued at $1,897,000 after acquiring an additional 65,438 shares during the last quarter.

More Jade Biosciences News

Here are the key news stories impacting Jade Biosciences this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and assigned a $55 price target, implying approximately 291.5% upside from the referenced $14.05 share price. The target signals substantial analyst confidence in Jade’s pipeline and could improve investor sentiment. Benzinga analyst rating report
• Positive Sentiment: Jade reported preclinical data for JADE301, a half-life-extended anti-IFN-β monoclonal antibody being developed for dermatomyositis. The candidate showed selective, high-affinity IFN-β binding and greater functional potency than the dazukibart comparator in disease-relevant human cells. Jade Biosciences JADE301 preclinical data announcement
• Positive Sentiment: In non-human primates, subcutaneous JADE301 demonstrated an approximately 25-day half-life, predictable distribution into muscle and good tolerability across tested doses. These characteristics could support less frequent dosing and a differentiated product profile if confirmed clinically. Jade Biosciences advances JADE301 toward Phase 1
• Neutral Sentiment: Jade expects to begin a Phase 1 healthy-volunteer trial in the fourth quarter of 2026, with interim data anticipated in the second half of 2027. The clinical timeline provides a near-term catalyst, but meaningful efficacy and safety validation remain ahead. Jade Biosciences JADE301 announcement
• Negative Sentiment: The data are preclinical and do not establish that JADE301 will benefit patients or succeed in clinical trials. With shares below their 50-day and 200-day moving averages, investors may remain sensitive to development delays, trial setbacks and future financing needs.

About Jade Biosciences

Jade Biosciences, Inc (NASDAQ: JBIO) is a clinical-stage biotechnology company focused on developing medicines for autoimmune and inflammatory diseases. The company uses antibody-based drug discovery and development approaches to pursue therapies intended to address significant unmet medical needs.

Jade Biosciences is advancing a pipeline of investigational programs and does not currently have commercially marketed products. Its work is centered on identifying and developing targeted therapies that may modulate biological pathways involved in autoimmune disease.

The company’s activities primarily consist of research, preclinical development and clinical evaluation of its drug candidates.